Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals announced FDA approval of its romidepsin injection solution, a ready-to-use formulation that simplifies hospital and pharmacy preparation compared to the previously marketed lyophilized powder. The product’s Competitive Generic Therapy designation grants Amneal 180 days of market exclusivity, enhancing its differentiated inje…